USA Domestic Delivery,Canada Domestic Delivery,European Domestic Delivery

Ulipristal Powder (159811-51-5)

Rating: SKU: 159811-51-5. Category:

AASraw is with synthesis and production ability from gram to mass order of Ulipristal Powder (159811-51-5), under CGMP regulation and trackable quality control system.

blank

Product Description

 

Ulipristal Powder (159811-51-5) video

 

 


 

Ulipristal Powder (159811-51-5) Specification:

 

Chemical Structure: Product Name: Ulipristal
Buy Ulipristal Powder (159811-51-5) hplc≥98% | AASraw Cas No.: 159811-51-5
Molecular Formula: C28H35NO3
Molecular Weight: 433.5824
Synonyms: 11β-[4-(N,N-Dimethylamino)-phenyl]-17α-hydroxy-19-norpregna-4,9-diene-3,20-dione;
Storage: Store at room temperature away from light and moisture.
Documents(COA & HPLC etc.): Available

 

Ulipristal Powder (159811-51-5) Description:

Ulipristal is an emergency contraceptive. It works by stopping or delaying the release of an egg from an ovary. Ulipristal may also make it harder for a fertilized egg to attach to the uterus.

Ulipristal powder is used to prevent pregnancy after having sex without using a condom or other effective birth control method. Ulipristal is also used to prevent pregnancy after a regular form of birth control has failed. Ulipristal is not to be used as a regular form of daily, weekly, or monthly birth control.Ulipristal is not to be used as a regular form of daily, weekly, or monthly birth control.Ulipristal can harm an unborn baby or cause birth defects. Do not use if you are already pregnant or think you might be pregnant.

Ulipristal powder is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity.

 

Reference:

  • Courtoy, Guillaume E.; Donnez, Jacques; Marbaix, Etienne; Dolmans, Marie-Madeleine (2015). “In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment”. Fertility and Sterility. 104 (2): 426–34.e1. doi:10.1016/j.fertnstert.2015.04.025. PMID 26003270.
  • Emma Hitt (18 June 2010). “FDA Panel Gives Ulipristal Acetate Unanimous Positive Vote for Emergency Contraception Indication”. Archived from the original on 9 March 2011. Retrieved 22 June 2010.
  •  Watson PR (1 December 2010). “Watson Launches ella(R)(ulipristal acetate)”. Retrieved 12 January 2010.